William Johnson Irvin Jr. MD

Oncology•Midlothian, VA

Assistant Professor, Medicine, University of North Carolina-Chapel Hill School of Medicine

Join to View Full Profile

14051 St Francis BlvdSuite 2210Midlothian, VA 23114
Phone+1 804-893-8717
Fax+1 804-594-3131

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2003 - 2006
Virginia Commonwealth University School of MedicineClass of 2003

Certifications & Licensure

NC State Medical License 2006 - 2026
VA State Medical License 2003 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Completed
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
ACTIVE_NOT_RECRUITING
PHASE3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
Stephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, Matthew L Kosel, Vered Stearns
Breast Cancer Research and Treatment. 2025-05-01
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.
Hanna Bandos, Sungjin Kim, N Lynn Henry, Ron D Hays, Vinicius F Calsavara
JNCI Cancer Spectrum. 2025-04-30
1 citations
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Hanna K Sanoff, Allison M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy
The Oncologist. 2024-09-06

Press Mentions

Bon Secours Offering New Therapy to Help Reduce Hair Loss Caused by ChemoOctober 2nd, 2019
How the Sisters Network Plans to Save Women’s Lives This YearSeptember 27th, 2019
Medical Options for the Treatment of Breast Cancer on Coast LiveOctober 26th, 2018

Grant Support

NCI Community Oncology Research Program 2025 Extension RequestSOUTHEAST CLINICAL ONCOL RES CONSORTIUM2014–2026